Pharmacosmos GmbH
About Pharmacosmos
editPharmacosmos is a globally operating, family-run pharmaceutical company with Danish roots and over 50 years of experience in developing innovative treatments and solutions based on iron and carbohydrates for human and veterinary use. The company has established itself as a world-leading authority in the treatment of iron deficiency anemia.
The focus is on carbohydrate chemistry and the development of medicines, especially in the field of iron deficiency and anemia. Pharmacosmos has set itself the goal of fundamentally changing the way iron deficiency is prevented and treated. The company strives to become the world's preferred partner in the management of iron deficiency and iron deficiency anemia by simplifying treatment, improving patient safety and promoting the use of high-dose, intravenous iron in various therapeutic areas.
Pharmacosmos is a research-based company whose ongoing research and development program focuses on improving the lives of patients with iron deficiency, with or without anemia. The company is also developing Petadeferitrin, a novel iron chelator, as an innovative treatment for patients with transfusion-related iron overload.
The company values an inclusive and appreciative corporate culture that promotes teamwork, open communication and ethical behavior. Pharmacosmos is aware of its social responsibility and is committed to healthy and sustainable societies. The company does not compromise on quality or business ethics and makes ethically sound decisions even in difficult situations.
Pharmacosmos has a strong global presence and its products are marketed in over 80 countries worldwide. The company has subsidiaries in the USA, China, Great Britain, Ireland, Germany, Sweden and Norway. The production facilities are approved by, among others, the Danish Medicines Agency and the US FDA.
